NTRB - NASDAQ
Nutriband Inc.
$4.15
-0.72%Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
At a Glance
Live Snapshotntrb
Total Current Assets
Last Annual Value
4.79M
3-Year CAGR
-4%
5-Year CAGR
156%
10-Year CAGR
161%
Nutriband Inc. Competitors Analysis of Total Current Assets
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Nutriband Inc. NASDAQ:NTRB | 4.79M | 67.4% | -2.6% | 62.3% | |
 TScan Therapeutics, Inc. NASDAQ:TCRX | 152.41M | -7.8% | -1.7% | N/A | |
 Relmada Therapeutics, Inc. NASDAQ:RLMD | 93.98M | -1.2% | -15.9% | 43.9% | |
 XBiotech Inc. NASDAQ:XBIT | 126.95M | -14.3% | -12.5% | 13.1% | |
 Acrivon Therapeutics, Inc. Common Stock NASDAQ:ACRV | 120.44M | -2.4% | 3.7% | N/A | |
 Adicet Bio, Inc. NASDAQ:ACET | 160.93M | -0.3% | -10.6% | -7.5% | |
 Gain Therapeutics, Inc. NASDAQ:GANX | 22.24M | 7.7% | -10.0% | N/A | |
 MindWalk Holdings Corp. NASDAQ:HYFT | 18.75M | 3.8% | -17.4% | 31.4% | |
 Vaxart, Inc. NASDAQ:VXRT | 115.15M | 36.2% | -7.4% | 11.2% | |
 ImageneBio Inc NASDAQ:IMA | 140.29M | -7.7% | -9.9% | N/A | |
 Immunic, Inc. NASDAQ:IMUX | 22.87M | -24.2% | -26.3% | -9.4% |
Nutriband Inc. Fair Value Envelope
Related Guides
Continue your NTRB research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.